Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas
Cushing's disease is a severe clinical condition caused by hypersecretion of corticosteroids due to excessive ACTH secretion from a pituitary adenoma. This complex endocrine disorder still represents a major challenge for the physician in terms of efficient treatment. In the last years there wa...
Guardado en:
| Autores principales: | , |
|---|---|
| Publicado: |
2009
|
| Materias: | |
| Acceso en línea: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_13899155_v10_n2_p103_Labeur http://hdl.handle.net/20.500.12110/paper_13899155_v10_n2_p103_Labeur |
| Aporte de: |
| id |
paper:paper_13899155_v10_n2_p103_Labeur |
|---|---|
| record_format |
dspace |
| spelling |
paper:paper_13899155_v10_n2_p103_Labeur2023-06-08T16:13:12Z Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas Labeur, Marta Susana Páez Pereda, Marcelo Corticotrophinomas Cushing's disease Pituitary adenomas Retinoic acid Retinoic acid receptors alitretinoin alpha tocopherol bexarotene bone morphogenetic protein 4 cell nucleus receptor corticosteroid corticotropin gamma interferon isotretinoin ketoconazole paclitaxel r 667 retinoic acid retinoic acid derivative retinoic acid receptor alpha retinoic acid receptor beta retinoic acid receptor gamma retinoid X receptor tazarotene uab 30 unclassified drug acne ACTH secreting adenoma actinic keratosis alopecia areata antineoplastic activity atopic dermatitis brain cancer breast cancer colorectal cancer conjunctivitis corticotropin release Cushing disease cutaneous T cell lymphoma drug half life drug intermittent therapy drug mechanism drug megadose drug safety drug targeting emphysema glioma head and neck cancer hormone action human hyperkeratosis juvenile myelomonocytic leukemia Kaposi sarcoma kidney cancer liver function liver toxicity lung non small cell cancer lung small cell cancer melanoma mucosa inflammation mycosis fungoides nephroblastoma neuroblastoma nonhuman photosensitivity promyelocytic leukemia prostate cancer psoriasis review side effect T cell leukemia T cell lymphoma teratogenicity verruca vulgaris ACTH-Secreting Pituitary Adenoma Animals Antineoplastic Agents Humans Pituitary ACTH Hypersecretion Pituitary Neoplasms Tretinoin Cushing's disease is a severe clinical condition caused by hypersecretion of corticosteroids due to excessive ACTH secretion from a pituitary adenoma. This complex endocrine disorder still represents a major challenge for the physician in terms of efficient treatment. In the last years there was only little progress in elucidating the molecular mechanisms responsible for the constitutive and autonomous ACTH secretion of pituitary corticotrophinomas. As a consequence, no effective drug therapy is currently available, particularly if surgical excision is not successful. In the present article we examine recent studies that have investigated the therapeutic potential of retinoic acid receptors as nuclear receptor targets for the treatment of Cushing's disease. Retinoic acid is an efficient drug used for the treatment of different types of cancers and it proved to act in animal models of Cushing's disease. The efficiency of this treatment in patients with this disorder still needs to be tested in clinical trials. © 2008 Springer Science+Business Media, LLC. Fil:Labeur, M. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Paez-Pereda, M. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. 2009 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_13899155_v10_n2_p103_Labeur http://hdl.handle.net/20.500.12110/paper_13899155_v10_n2_p103_Labeur |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
Corticotrophinomas Cushing's disease Pituitary adenomas Retinoic acid Retinoic acid receptors alitretinoin alpha tocopherol bexarotene bone morphogenetic protein 4 cell nucleus receptor corticosteroid corticotropin gamma interferon isotretinoin ketoconazole paclitaxel r 667 retinoic acid retinoic acid derivative retinoic acid receptor alpha retinoic acid receptor beta retinoic acid receptor gamma retinoid X receptor tazarotene uab 30 unclassified drug acne ACTH secreting adenoma actinic keratosis alopecia areata antineoplastic activity atopic dermatitis brain cancer breast cancer colorectal cancer conjunctivitis corticotropin release Cushing disease cutaneous T cell lymphoma drug half life drug intermittent therapy drug mechanism drug megadose drug safety drug targeting emphysema glioma head and neck cancer hormone action human hyperkeratosis juvenile myelomonocytic leukemia Kaposi sarcoma kidney cancer liver function liver toxicity lung non small cell cancer lung small cell cancer melanoma mucosa inflammation mycosis fungoides nephroblastoma neuroblastoma nonhuman photosensitivity promyelocytic leukemia prostate cancer psoriasis review side effect T cell leukemia T cell lymphoma teratogenicity verruca vulgaris ACTH-Secreting Pituitary Adenoma Animals Antineoplastic Agents Humans Pituitary ACTH Hypersecretion Pituitary Neoplasms Tretinoin |
| spellingShingle |
Corticotrophinomas Cushing's disease Pituitary adenomas Retinoic acid Retinoic acid receptors alitretinoin alpha tocopherol bexarotene bone morphogenetic protein 4 cell nucleus receptor corticosteroid corticotropin gamma interferon isotretinoin ketoconazole paclitaxel r 667 retinoic acid retinoic acid derivative retinoic acid receptor alpha retinoic acid receptor beta retinoic acid receptor gamma retinoid X receptor tazarotene uab 30 unclassified drug acne ACTH secreting adenoma actinic keratosis alopecia areata antineoplastic activity atopic dermatitis brain cancer breast cancer colorectal cancer conjunctivitis corticotropin release Cushing disease cutaneous T cell lymphoma drug half life drug intermittent therapy drug mechanism drug megadose drug safety drug targeting emphysema glioma head and neck cancer hormone action human hyperkeratosis juvenile myelomonocytic leukemia Kaposi sarcoma kidney cancer liver function liver toxicity lung non small cell cancer lung small cell cancer melanoma mucosa inflammation mycosis fungoides nephroblastoma neuroblastoma nonhuman photosensitivity promyelocytic leukemia prostate cancer psoriasis review side effect T cell leukemia T cell lymphoma teratogenicity verruca vulgaris ACTH-Secreting Pituitary Adenoma Animals Antineoplastic Agents Humans Pituitary ACTH Hypersecretion Pituitary Neoplasms Tretinoin Labeur, Marta Susana Páez Pereda, Marcelo Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas |
| topic_facet |
Corticotrophinomas Cushing's disease Pituitary adenomas Retinoic acid Retinoic acid receptors alitretinoin alpha tocopherol bexarotene bone morphogenetic protein 4 cell nucleus receptor corticosteroid corticotropin gamma interferon isotretinoin ketoconazole paclitaxel r 667 retinoic acid retinoic acid derivative retinoic acid receptor alpha retinoic acid receptor beta retinoic acid receptor gamma retinoid X receptor tazarotene uab 30 unclassified drug acne ACTH secreting adenoma actinic keratosis alopecia areata antineoplastic activity atopic dermatitis brain cancer breast cancer colorectal cancer conjunctivitis corticotropin release Cushing disease cutaneous T cell lymphoma drug half life drug intermittent therapy drug mechanism drug megadose drug safety drug targeting emphysema glioma head and neck cancer hormone action human hyperkeratosis juvenile myelomonocytic leukemia Kaposi sarcoma kidney cancer liver function liver toxicity lung non small cell cancer lung small cell cancer melanoma mucosa inflammation mycosis fungoides nephroblastoma neuroblastoma nonhuman photosensitivity promyelocytic leukemia prostate cancer psoriasis review side effect T cell leukemia T cell lymphoma teratogenicity verruca vulgaris ACTH-Secreting Pituitary Adenoma Animals Antineoplastic Agents Humans Pituitary ACTH Hypersecretion Pituitary Neoplasms Tretinoin |
| description |
Cushing's disease is a severe clinical condition caused by hypersecretion of corticosteroids due to excessive ACTH secretion from a pituitary adenoma. This complex endocrine disorder still represents a major challenge for the physician in terms of efficient treatment. In the last years there was only little progress in elucidating the molecular mechanisms responsible for the constitutive and autonomous ACTH secretion of pituitary corticotrophinomas. As a consequence, no effective drug therapy is currently available, particularly if surgical excision is not successful. In the present article we examine recent studies that have investigated the therapeutic potential of retinoic acid receptors as nuclear receptor targets for the treatment of Cushing's disease. Retinoic acid is an efficient drug used for the treatment of different types of cancers and it proved to act in animal models of Cushing's disease. The efficiency of this treatment in patients with this disorder still needs to be tested in clinical trials. © 2008 Springer Science+Business Media, LLC. |
| author |
Labeur, Marta Susana Páez Pereda, Marcelo |
| author_facet |
Labeur, Marta Susana Páez Pereda, Marcelo |
| author_sort |
Labeur, Marta Susana |
| title |
Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas |
| title_short |
Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas |
| title_full |
Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas |
| title_fullStr |
Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas |
| title_full_unstemmed |
Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas |
| title_sort |
potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas |
| publishDate |
2009 |
| url |
https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_13899155_v10_n2_p103_Labeur http://hdl.handle.net/20.500.12110/paper_13899155_v10_n2_p103_Labeur |
| work_keys_str_mv |
AT labeurmartasusana potentialofretinoicacidderivativesforthetreatmentofcorticotrophpituitaryadenomas AT paezperedamarcelo potentialofretinoicacidderivativesforthetreatmentofcorticotrophpituitaryadenomas |
| _version_ |
1768546175120572416 |